Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a... see more

TSX:SVA - Post Discussion

Sernova Corp > Can Frank Hollyer perform as Executive Chairman?
View:
Post by steadfast on Dec 02, 2021 12:43pm

Can Frank Hollyer perform as Executive Chairman?

I, among many other shareholders felt he was useless as SVA Chairman.
I did not vote for him last AGM.  I understand he has performed well in the
past with other companies.  Let's tell him to JUST GET THE JOB DONE AND
NOW.  If I were him, I would immediately:

1.  Have Life Science phone GINA KOLATA, NY Times - Have I got a story for you,
one that is much better than you recently wrote re Diabetes.  LIfe Sciences have
the data, our patients are brittle diabetics, the sickest of the sickest, and relay
our study of Patient #1.  Have Life Sciences review VX-880 one year to reduce
HbA1c 1% from Baseline.  SVA wins this one.

Arrange for Life Sciences to get top quality news coverage for SVA.

2.  Time for Ray Matthews & Life Sciences to perform or "out the door".
At time of typing this,  35,000 shares traded on TSX, DJ +632.
Days of Old Boys Club is over.

3.  Time to sign a deal with a Device Manufacturer and Big Pharma that is
best for shareholders.

4.  Time for Cannacord to keep their promise of an Analyst Report.

5.  How about JDRF US Website include SVA & U of Chicago Clinical Trial,
SVA should get coverage, not just ViaCyte.

6.  Keep SVA well ahead of the competition
Comment by BioTeck on Dec 02, 2021 12:47pm
Don't forget the TSX listing. Frank will get it all done. 
Comment by steadfast on Dec 02, 2021 12:58pm
I do not want a TSX Listing for SVA.  I would like to go directly to Nasdaq. Good point, I should have included it.  One more job for him to get done.
Comment by Metalsguy1 on Dec 03, 2021 11:27am
steadfast. Holler and Matthews are buddies. How do you think Ray has lasted this long?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities